Region
CDMOs in South America
Compare South American CDMOs across Brazil, Argentina, Chile, and Colombia. Filter by manufacturing type, regulatory approvals, and capacity.
30 companies listed
South American CDMO Manufacturing
South America's pharmaceutical manufacturing capabilities are anchored by Brazil and Argentina, with growing contributions from Colombia and Chile. The region has particular strength in generics, biosimilars, and vaccine production. Government health programs in Brazil (SUS) and Argentina drive significant domestic demand for locally manufactured pharmaceuticals.
Brazil accounts for approximately 50% of the South American pharmaceutical market. CDMOs in Sao Paulo and Rio de Janeiro corridors offer oral solid dose, sterile manufacturing, and increasingly biologics capabilities. Argentina's pharmaceutical industry has a long tradition of innovation, with biosimilar expertise dating back to the early 2000s and strong analytical capabilities.
Regional integration through MERCOSUR and Pacific Alliance trade agreements facilitates cross-border pharmaceutical supply chains. CDMOs that hold GMP certifications recognized across multiple South American markets can serve as regional manufacturing hubs for global pharma companies.
Companies (30)
Catalent Pharma Solution
Argentina
Catalent is a leading global CDMO trusted by pharma, biotech, and self-care companies to accelerate the development, manufacturing, and delivery of products that improve lives. With a worldwide network of facilities, advanced technologies, and deep expertise, Catalent provides integrated end-to-end solutions spanning oral dose, biologics, specialty therapies, cell and gene therapy, and clinical supply. The company partners with innovators from early-stage design through commercial manufacturing.
Small Molecule Drug ProductOral Solid DoseFormulation Development
Insud Pharma
Argentina
Insud Pharma is a large, diversified Spanish multinational pharmaceutical group with over 45 years of experience, 10,000 professionals, and 20 industrial plants across more than 50 countries. The company operates API manufacturing, oral solid dose, and injectable manufacturing through its CMO division (Chemo CMO), and biologics/biosimilar manufacturing through its biotech unit mAbxience (majority stake sold to Fresenius Kabi in 2022).
Frequently Asked Questions
What role does Brazil play in South American pharmaceutical manufacturing?+
Brazil is the dominant pharmaceutical manufacturing market in South America, with ANVISA enforcing PIC/S-aligned GMP standards. The country has invested in domestic manufacturing capacity through public-private partnerships (especially through Fiocruz and Bio-Manguinhos for vaccines). Brazilian CDMOs handle oral solid dose, injectables, and are building biologics capacity. ANVISA pre-qualification facilitates exports to other LATAM markets.
Are South American CDMOs suitable for global supply?+
For regional supply to Latin American markets, South American CDMOs are well-suited and offer regulatory familiarity advantages. For global supply (US, EU, Japan), most South American CDMOs would need additional FDA/EMA inspections and certifications. Some Brazilian and Argentine facilities already hold FDA registration. The primary use case for global pharma companies is leveraging South American CDMOs for regional market access and clinical trial material supply.
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
